Mind.Px provides clinically actionable information to physicians prior to treatment choice that significantly reduces “trial and error” biologic drug prescribing behavior, leading to improved psoriasis patient outcomes and reductions in wasted spending
SAN DIEGO, CA – July 26, 2022 – Mindera Health announces the publication, in the Journal of Drugs in Dermatology, of the recommendations from an expert consensus panel that supports adequate demonstration of clinical utility of the flagship Mind.Px precision medicine test if positive results from the MATCH Study are achieved.
Agreed-upon proof of clinical utility in a real-world setting is defined as the concordant use of test results by a physician in patient management decision-making that results in a positive health benefit for the patient. It is often required to eliminate barriers to coverage by payers, with the…